Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.
Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2026
Preclinical evaluation of trastuzumab deruxtecan in a new HER2+ leptomeningeal colonization model.
Journal: Cancer letters
Published: March 13, 2026
Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative.
Journal: Neuro-oncology
Published: July 24, 2025
Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.
Journal: Neuro-oncology
Published: July 24, 2025
Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.
Journal: Neuro-oncology advances
Published: April 25, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Journal: Nature communications
Published: April 02, 2025
A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models.
Journal: Clinical & experimental metastasis
Published: February 05, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.
Journal: Cancer medicine
Published: August 17, 2024
Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting.
Journal: Frontiers in oncology
Published: March 04, 2024
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 26, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Journal: The oncologist
Published: April 14, 2023
Last Updated: 09/26/2026